You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Pfizer, Myovant begin dosing in relugolix contraceptive study

Pfizer and Myovant have announced that dosing has begun in a Phase III study evaluating the contraceptive efficacy of their relugolix combination tablet.